Key Dates
|
Symposium dates: 2nd & 3rd November 2023
Early bird registration closes: 29 September 2023 Full registration registration closes: 26 October 2023 |
#TAS2023
|
Breaking NEWS: Due to popular demand Early Bird Registration has been extended to Friday 29th September - be quick to take advantage of this extended opportunity for a $100 discount.
Latest NEWS: We announce a new award for "Best Speaker Selected from Submitted Abstracts" which comes with a $500 prize.
Latest NEWS: We announce a new award for "Best Speaker Selected from Submitted Abstracts" which comes with a $500 prize.
Welcome
On behalf of the organizing committee we are excited to announce the 9th Thomas Ashworth CTC & Liquid Biopsy Symposium will be held as an in-person event at Peter MacCallum Cancer Centre, Melbourne on the 2nd and 3rd November 2023. The registration desk and the spacious well-designed symposium lecture hall is located on 7th floor. We hope the setting will inspire both speakers and delegates to engage enthusiastically to advance liquid biopsy research its clinical implementation.
The Symposium will run over 2 days enabling us to cover cutting-edge advances in liquid biopsy translational research and clinical applications. The program will begin at 9am on Thursday 2nd November and close at 5pm on Friday3rd November.
The aim of the Symposium is to enrich our understanding of the clinical application of liquid biopsy and improve patient outcomes, as well as provide critical insights into the metastatic process and application of liquid biopsy in different contexts. Topics that will be explored include circulating tumour cells, exosomes, methylated ctDNA, assay development, early detection, integration of liquid biopsy into clinical trials and precision oncology, treatment selection and monitoring as well as drug resistance monitoring.
An exciting line up of invited keynote speakers who are leaders in the field will be showcasing their liquid biopsy research. In addition, invited speakers and speakers selected from submitted abstracts from across Australia, New Zealand and Asia will present their latest research. Two panel discussions are included in the program and are designed to highlight patient perspectives and health professional views with the intent to stimulate debate and are a symposium highlight.
The Symposium will run over 2 days enabling us to cover cutting-edge advances in liquid biopsy translational research and clinical applications. The program will begin at 9am on Thursday 2nd November and close at 5pm on Friday3rd November.
The aim of the Symposium is to enrich our understanding of the clinical application of liquid biopsy and improve patient outcomes, as well as provide critical insights into the metastatic process and application of liquid biopsy in different contexts. Topics that will be explored include circulating tumour cells, exosomes, methylated ctDNA, assay development, early detection, integration of liquid biopsy into clinical trials and precision oncology, treatment selection and monitoring as well as drug resistance monitoring.
An exciting line up of invited keynote speakers who are leaders in the field will be showcasing their liquid biopsy research. In addition, invited speakers and speakers selected from submitted abstracts from across Australia, New Zealand and Asia will present their latest research. Two panel discussions are included in the program and are designed to highlight patient perspectives and health professional views with the intent to stimulate debate and are a symposium highlight.
Confirmed Keynote Speakers
|
Professor Razelle Kurzrock MD Professor of Medicine, Associate Director, Clinical Research, Linda T. And John A. Mellowes Endowed,Chair Precision Oncology, Founding Director, Michels Rare Cancers Research Laboratories, MCW Cancer Center, USA |
|
Professor Jonathan Karpelowsky MBBCh. FCS. Cert Paed Surg. FRACS. PhD Professor of Paediatric Surgery Division of Child and Adolescent Health Children's Hospital Westmead, University of Sydney, AUS |
|
Associate Professor Geoffrey Oxnard, MD Senior Vice President, Head of Clinical Development, Global Medical Lead, Liquid Portfolio, Foundation Medicine, USA |
SUBMIT AN ABSTRACT The opportunity to submit abstracts for oral and poster presentations is available. All abstracts will be reviewed by a panel and those chosen for oral presentation will be notified prior to the Symposium. Submissions are welcome from all delegates. For young investigators generous prizes will be awarded to rapid fire oral presentation finalists and the best poster - the abstract submission deadline is Friday 29th September 5pm.
ACCOMMODATION OPTIONS and link to hotels are on the Destination page.
Who should attend?
The organizing committee maintains a philosophy of keeping registration costs as low as possible to encourage attendance and this is only possible through the generous support of our sponsors. So please ensure to visit the exhibitor tables and check out their latest product offerings.
We look forward to seeing you at the Symposium in November.
ACCOMMODATION OPTIONS and link to hotels are on the Destination page.
Who should attend?
- Translational/clinical researchers
- Medical oncologists
- Pathologists
- Patient advocates
- Clinical trainees, PhD and other students
- Pharmaceutical and diagnostic sector
The organizing committee maintains a philosophy of keeping registration costs as low as possible to encourage attendance and this is only possible through the generous support of our sponsors. So please ensure to visit the exhibitor tables and check out their latest product offerings.
We look forward to seeing you at the Symposium in November.
|
|
Dr Stephen Wong and Associate Professor Kevin Spring
C0-convenors, 9th Thomas Ashworth CTC & Liquid Biopsy Symposium
C0-convenors, 9th Thomas Ashworth CTC & Liquid Biopsy Symposium
Diamond Sponsor
Platinum Sponsors
|
|
|
Institutional Sponsor
Organizing Committee
Dr. Stephen Wong (Co-convenor) Peter MacCallum Cancer Centre, Melbourne
A/Prof. Kevin Spring (C0-convenor), Ingham Institute, Western Sydney University, Sydney
A/Prof. Therese Becker, Ingham Institute, Sydney
A/Prof. Mark Cowley, Children's Cancer Institute, Sydney
A/Prof. Alex Dobrovic, University of Melbourne, Melbourne
A/Prof. Elin Gray, Edith Cowen University, Perth
A/Prof. Craig Gedye, Calvary Mater Newcastle & Hunter Medical Research Institute, University of Newcastle, Newcastle
Prof. Chamindie Punyadeera, Griffith University, Brisbane
Prof. Rik Thompson, QUT, Brisbane
Dr Kristina Warton, UNSW, Sydney
Dr Dineika Chandrananda, Peter MacCallum Cancer Centre, Melbourne
Dr Heidi Fettke, Peter MacCallum Cancer Centre, Melbourne
For more information please contact Dr Stephen Wong - [email protected] or A/Prof Kevin Spring - [email protected]
Dr. Stephen Wong (Co-convenor) Peter MacCallum Cancer Centre, Melbourne
A/Prof. Kevin Spring (C0-convenor), Ingham Institute, Western Sydney University, Sydney
A/Prof. Therese Becker, Ingham Institute, Sydney
A/Prof. Mark Cowley, Children's Cancer Institute, Sydney
A/Prof. Alex Dobrovic, University of Melbourne, Melbourne
A/Prof. Elin Gray, Edith Cowen University, Perth
A/Prof. Craig Gedye, Calvary Mater Newcastle & Hunter Medical Research Institute, University of Newcastle, Newcastle
Prof. Chamindie Punyadeera, Griffith University, Brisbane
Prof. Rik Thompson, QUT, Brisbane
Dr Kristina Warton, UNSW, Sydney
Dr Dineika Chandrananda, Peter MacCallum Cancer Centre, Melbourne
Dr Heidi Fettke, Peter MacCallum Cancer Centre, Melbourne
For more information please contact Dr Stephen Wong - [email protected] or A/Prof Kevin Spring - [email protected]
Copyright 2023 ThomasAshworthSymposium